Home Tags FRα

Tag: FRα

Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...

Danielle Garcia
Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...

MORAb-202 has Potential Anti-tumor Effects in Breast Cancer

ADC Review | Editorial Team
MORAb-202, Eisai’s first antibody-drug conjugate, targets FRα-positive solid tumors. The investigational agent is composed of the company’s in-house developed anticancer agent farletuzumab, a humanized...

ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers

Peter Hofland
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...

Companion Diagnostics: Paving the Way for Personalized Medicine

Peter Hofland
There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X